» Articles » PMID: 35162921

Patients' Views on the Design of DiabeText, a New MHealth Intervention to Improve Adherence to Oral Antidiabetes Medication in Spain: A Qualitative Study

Abstract

Background: Type 2 Diabetes Mellitus (T2DM) is a long-term condition affecting around 10% of people worldwide. This study aimed to explore T2DM patients' views on DiabeText, a new text messaging intervention to be developed to support adherence to diabetes medication.

Methods: A total of four focus groups were conducted with a purposive sample of people with T2DM (n = 34). The data were analysed by multiple researchers independently, and coded using thematic analysis.

Results: There were two main themes that emerged: (1) "patients' perspectives on unmet needs for diabetes self-management", and (2) "acceptability and perceived utility of DiabeText". The patients identified a number of barriers for diabetes self-management, including lack of appropriate information and support with diet and physical activity. Support for medication-taking was not perceived as urgently needed, although several barriers were identified (eating outside, traveling, polymedication, dispensation at the pharmacy). The participants anticipated that the proposed intervention would present high levels of patient acceptability and perceived utility as long as its content addresses the barriers that were identified, and includes specific features (short and clear messages, and personalized information).

Conclusion: The proposed intervention has the potential to be well accepted and perceived as useful by T2DM patients who require support not only in terms of medication-taking, but more prominently of lifestyle behaviour.

Citing Articles

Impact of an SMS intervention to support type 2 diabetes self-management: DiabeText clinical trial.

Zamanillo-Campos R, Fiol-deRoque M, Serrano-Ripoll M, Llobera-Canaves J, Llobera J, Taltavull-Aparicio J Br J Gen Pract. 2024; .

PMID: 39362693 PMC: 11755587. DOI: 10.3399/BJGP.2024.0206.


Opening the Black Box of an mHealth Patient-Reported Outcome Tool for Diabetes Self-Management: Interview Study Among Patients With Type 2 Diabetes.

Marini C, Cruz J, Payano L, Flores R, Arena G, Mandal S JMIR Form Res. 2023; 7:e47811.

PMID: 37725427 PMC: 10548328. DOI: 10.2196/47811.


Development and Evaluation of a Digital Health Intervention to Prevent Type 2 Diabetes in Primary Care: The PREDIABETEXT Study Protocol for a Randomised Clinical Trial.

Galmes-Panades A, Angullo E, Mira-Martinez S, Bennasar-Veny M, Zamanillo-Campos R, Gomez-Juanes R Int J Environ Res Public Health. 2022; 19(22).

PMID: 36429423 PMC: 9690330. DOI: 10.3390/ijerph192214706.


Perspectives and Views of Primary Care Professionals Regarding DiabeText, a New mHealth Intervention to Support Adherence to Antidiabetic Medication in Spain: A Qualitative Study.

Zamanillo-Campos R, Serrano-Ripoll M, Taltavull-Aparicio J, Gervilla-Garcia E, Ripoll J, Fiol-deRoque M Int J Environ Res Public Health. 2022; 19(7).

PMID: 35409916 PMC: 8999018. DOI: 10.3390/ijerph19074237.

References
1.
Saini S, Schoenfeld P, Kaulback K, Dubinsky M . Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009; 15(6):e22-33. View

2.
Krass I, Schieback P, Dhippayom T . Adherence to diabetes medication: a systematic review. Diabet Med. 2014; 32(6):725-37. DOI: 10.1111/dme.12651. View

3.
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M . Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008; 337:a1655. PMC: 2769032. DOI: 10.1136/bmj.a1655. View

4.
Jankowska-Polanska B, Swiatoniowska-Lonc N, Karniej P, Polanski J, Tanski W, Grochans E . Influential factors in adherence to the therapeutic regime in patients with type 2 diabetes and hypertension. Diabetes Res Clin Pract. 2021; 173:108693. DOI: 10.1016/j.diabres.2021.108693. View

5.
Gil-Girbau M, Aznar-Lou I, Penarrubia-Maria M, Moreno-Peral P, Fernandez A, Bellon J . Reasons for medication non-initiation: A qualitative exploration of the patients' perspective. Res Social Adm Pharm. 2019; 16(5):663-672. DOI: 10.1016/j.sapharm.2019.08.002. View